AlphAIAlphAI — Financial news for AI agents
quiverquant.comSEP 212 min read$CAH

CARDINAL HEALTH INC ($CAH) CEO 2026 Pay Revealed

Cardinal Health ($CAH) CEO Jason M. Hollar's 2026 compensation was estimated at $22.57M, up 15.94% from 2025. Insiders sold 31 times in the past 6 months, with no purchases. Analysts set a median price target of $245.0, and hedge funds showed mixed portfolio activity.

Original reporting
quiverquant.com
Published Sep 21, 2026, 10:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 10:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
CARDINAL HEALTH INC ($CAH) CEO 2026 Pay Revealed — source image
Source · quiverquant.com
Decision brief

The 30-second read

$CAHBearishLow
01

Why it matters

Provides insight into potential short-term price pressure due to insider sell-offs and high executive compensation.

02

Market read

Insider activity and compensation data are material for traders evaluating short-term risk on CAH.

03

What to watch

Recent large government contract awards ($256M) may offset concerns from insider sales.

Relevance 6/10Novelty 6/10Timing: Sept 21 2026 (today)

Background

The article compiles recent SEC Form 4 filings and contract award data for Cardinal Health.

Company-level read

Ticker impact

$CAHBearishMedium confidence
Context

SEC Form 4 shows CEO Jason Hollar earned $22.6M in 2026 and insiders sold ~200k shares in the past 6 months.

Expected impact

Potential modest downside pressure over the next few weeks.

Evidence & confidence

Large insider sales and elevated pay often signal concerns about future performance.

Market effects

Sector

Cardinal Health is a major player in healthcare distribution; insider activity may influence sector sentiment.

Regional

U.S. healthcare supply chain investors may reassess exposure.

Global

Limited to U.S. markets; minimal global impact.

Counterpoint

What could challenge this read

Insider sales could be routine portfolio rebalancing, not a bearish signal.

Key entities

  • Executive
    Jason M. Hollar

    CEO of Cardinal Health, received $22.6M compensation in 2026.

  • Company
    Cardinal Health Inc.

    U.S. healthcare services and products distributor.

Read at source← All news

Related articles

OCT 1
$MCKMed

McKesson (MCK) and Cardinal Health Extend CVS Health Distributio

McKesson (MCK) and Cardinal Health renewed their pharmaceutical distribution agreements with CVS Health, extending contracts through June 2032. Both companies reaffirmed their fiscal 2027 earnings guidance. McKesson's stock is trading at $890.28, 6.8% above its GF Value of $833.49, with a GF Score of 86/100. Insider sales totaled $28.3 million over the past year, while 15 premium gurus hold MCK with a net positive addition.

gurufocus.com2 min
OCT 1
$CAHMed

Why Is Cardinal Health and McKesson Stock Trading Higher Today - CVS Health (NYSE:CVS), McKesson (NYSE:MC

Cardinal Health (CAH) and McKesson (MCK) extended their distribution agreements with CVS Health (CVS) until 2032. Cardinal Health reaffirmed its 2027 adjusted earnings guidance of $12.40-$12.60 per share, while McKesson reiterated its 2027 outlook of $44.20-$45 per share. Both companies' stocks rose on the news, with McKesson up 4.28% and Cardinal Health up 2.94%.

benzinga.com2 min
OCT 1
$CAHMed

Cardinal Health (CAH) Extends CVS Distribution Deal Through 2032

Cardinal Health (CAH) extended its pharmaceutical distribution agreements with CVS Health through June 2032. The company reaffirmed its fiscal year 2027 non-GAAP EPS guidance of $12.40 to $12.60 and long-term growth range of 12% to 14%. The deal secures a key partnership and provides revenue visibility, though investors should note non-GAAP exclusions and industry pressures.

gurufocus.com2 min
OCT 1
$CAHMed

Cardinal Health Enters into Binding Letter of Intent to Extend Pharmaceutical Distribution Agreements with CVS Health

CARDINAL HEALTH INC (CAH) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Cardinal Health Enters into Binding Letter of Intent to Extend Pharmaceutical Distribution Agreements with CVS Health DUBLIN, Ohio, October 1, 2026 – Cardinal Health (NYSE: CAH) announced today that it has entered into a binding Letter of Intent to extend its existin

SEC EDGAR 8-K1 min